This is a Waived Complexity test for Urine, and Moderately Complex for Serum.



Similar documents
SAMPLE PROCEDURE , 09/11

OneStep Fecal Occult Blood RapiDip InstaTest. Cat #

CK-MB TEST CARD 004A302

What Does Having a FDA Cleared Pregnancy Test Mean?

Anti-Zona Pellucida Antibody Latex Agglutination Test

URINE DIPSTICK Multistix 10SG

Chapter. Guaiac Screening CHAPTER 4: GUAIAC TESTING SCREENING FOR OCCULT BLOOD. Page 1 of 5 Guaiac doc 6/24/2005

ABORhCard. ABORhCard Package Insert ABO and Rh Blood Grouping Device

Title: Glucose Testing: StatStrip Glucose Meter Page 1 of 6

Collection Instructions for ARUP Drug Screen Kit #49204

Intact PTH. system. Intact PTH /R5. Key to symbols used 8K25

Contents. Approved by: Kent Lewandrowski, M.D. 6/1/2005 Written/Updated by: Gino Pagnani Date: 4/3/09

Environmental Water Testing: Surface Water, Groundwater, Hard Water, Wastewater, & Seawater

TRIIODOTHYRONINE (T3) ELISA Kit Protocol

IgM ELISA. For the quantitative determination of IgM in human serum and plasma. For Research Use Only. Not For Use In Diagnostic Procedures.

Blood-Based Cancer Diagnostics

Mouse Insulin ELISA. For the quantitative determination of insulin in mouse serum and plasma

DHEA-S. system DHEA-S /R4. Key to symbols used 8K27

Mouse Creatine Kinase MB isoenzyme (CKMB) ELISA

Rat Creatine Kinase MB isoenzyme,ck-mb ELISA Kit

Biochemistry Validation Form

APPENDIX N BULK MILK TANKER SCREENING TEST FORM

Mouse IgM ELISA. Cat. No. KT-407 K-ASSAY. For the quantitative determination of IgM in mouse biological samples. For Research Use Only. 1 Rev.

Cold Agglutination Titer detecting Cold Reacting Antibodies

Cancer Antigen CA125 Human ELISA Kit

Content Sheet 5-1: Overview of Sample Management

POC.PC.17 Point of Care Testing AMNISURE PROCEDURE FOR RUPTURED FETAL MEMBRANES TABLE OF CONTENTS. 1.0 Principle of Procedure.. 2

REF. Intended Use. Summary and Explanation

Carcinoembryonic Antigen (CEA)

PROCEDURE COVERSHEET. Document Section: CHEMISTRY Author: JOANNE WONG Date Authored: JAN In Use Date: 2/1/2011 Discontinued Date:

SMF Awareness Seminar 2014

Cancer Antigen CA 125

Development and Validation of In Vitro Diagnostic Tests. YC Lee, Ph.D. CEO

STEP-BY-STEP INSTRUCTIONS FOR INVESTIGATIONAL USE. Rapid HCV Antibody Test FOR ORAQUICK RAPID HCV ANTIBODY TEST

Procedure: Quality Assurance Policy Version 5 Quality Assessment Policy Version 3

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

MEDICAL DEVICE GUIDANCE

FBS06 P30 Antigen Test for the Presence of Seminal Fluid

DRI Amphetamines Assay

Toxoplasma gondii IgM ELISA Kit Protocol

Rat Fibronectin ELISA Kit

Chapter 14 Urinalysis, Body Fluids and Other Specimens. Objectives:

EXERCISE 5: ERYTHROCYTES SEDIMENTATION RATE - ESR, SED RATE

General. What is a laboratory test? What is a waived test?

Hepatitis and Retrovirus. LIAISON XL Accurate detection of HIV infection. HIV Ab/Ag FOR OUTSIDE THE US AND CANADA ONLY

Inc. Wuhan. Quantity Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4 Standard (liquid) 2

Quality Control of the Future: Risk Management and Individual Quality Control Plans (IQCPs)

ab Free Testosterone ELISA Kit

Immunoglobulin E (IgE) concentrations in Human. Immunoglobulin E (IgE) Human ELISA Kit

Endocrinology of the Female Reproductive Axis

IgE (Human) ELISA Kit

Vaginal ph Test (ph Hydrion TM Paper )

Malondialdehyde (MDA) ELISA

Direct Antiglobulin Test (DAT)

The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C:

TEST METHOD VERIFICATION AND VALIDATION

Human Luteinizing Hormone (LH) Custom Kit

CDC-Lipid Standardization Program. Laboratory Data Collection System (LDCS) Instruction Manual

Please note: Contact Coppe Laboratories at if archival plasma samples need to be tested.

FDA Public Hearing on Clinical Accuracy Requirements for Point of Care Blood Glucose Meters (BGMs)

Laboratory Procedure Manual

Quality Requirements of a Point of Care Testing Service

Urinalysis Compliance Tools. POCC Webinar January 19, 2011 Dr. Susan Selgren

Direct Testing Systems and Serology

How to Verify Performance Specifications

INTRODUCTION. Viral shedding is crucial for Gene Therapy Products Safety linked with shedding data

Human Free Testosterone(F-TESTO) ELISA Kit

Premarital Screening Standard. Premarital Screening and Counseling Program. Version 1.1

XV.Quality Assurance in the Blood Bank

Understanding quantitative blood alcohol testing in drunk driving cases.

Hemoglobin Testing using the Data Management HemoCue Analyzer

Competency Assessment (both of employees and of the laboratory as a whole)

Unaccredited Point-of-Care Laboratory Testing Guideline for Physicians

BY UV SPECTROPHOTOMETRY

The Analytical & Clinical Complexities of Human Chorionic Gonadotropin Tests

Contents. Abstract...i. Committee Membership... iii. Foreword... vii. 1 Scope...1

Customer Service: Contact your local representative or find country specific contact information on Key to symbols used

Reference Range: mmol/l (arterial) mmol/l (venous) CPT Code: 83605

MTT Cell Proliferation Assay

Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988

RealLine HCV PCR Qualitative - Uni-Format

Human Parathyroid Hormone (PTH) ELISA Kit

How To Test For Creatinine

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

MANUAL WBC LAB OBJECTIVE

Intended Use: The kit is designed to detect the 5 different mutations found in Asian population using seven different primers.

LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)

USING CLSI GUIDELINES TO PERFORM METHOD EVALUATION STUDIES IN YOUR LABORATORY

your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.

Lab 2. Spectrophotometric Measurement of Glucose

MULTI-ARRAY. 1-Plate Kit 5-Plate Kit 20-Plate Kit

PRINCIPLE. REF (200 tests/cartridge) REF (400 tests/cartridge) ANNUAL REVIEW Reviewed by: Date. Date INTENDED USE

For In Vitro Diagnostic Use

Albumin ELISA Kit. Albumin ELISA Kit. Zur in vitro Bestimmung des Albumin in Urin und Stuhl

2010 Laboratory Accreditation Program Audioconference. Accreditation Requirements for Waived Vs. Non-waived Tests

BUTTE COUNTY PUBLIC HEALTH DEPARTMENT POLICY & PROCEDURE

Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions

ab Albumin Human ELISA Kit

MEDICAL NUTRITION THERAPY (MNT) CLINICAL NUTRITION THERAPY Service Time CPT Code

Subpart H--Participation in Proficiency Testing for Laboratories Performing Nonwaived Testing

Transcription:

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Laboratory Name: Laboratory Address: Date of this packet: Sure-Vue Serum/Urine hcg-stat Laboratory Procedure This procedure is intended to provide a ready outline reference for performance of the assay. These abbreviated directions for use are not intended to replace the complete package insert. Any modifications to this document are the sole responsibility of the Facility. This is a Waived Complexity test for Urine, and Moderately Complex for Serum. I. Intended Use The Sure-Vue Serum/Urine hcg-stat is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin (hcg) in urine and serum to aid in the early detection of pregnancy. II. Test Principle The Sure-Vue Serum/Urine hcg-stat is a rapid chromatographic immunoassay for the qualitative detection of human chorionic gonadotropin (hcg) in urine and serum to aid in the early detection of pregnancy. The test utilizes a combination of antibodies including mouse monoclonal anti-hcg antibodies and goat polyclonal anti-hcg antibodies to selectively detect elevated levels of hcg. The assay is conducted by adding serum or urine specimen to the specimen well of the test device and observing the formation of colored lines. The specimen migrates via capillary action along the membrane to react with the colored conjugate. Positive specimens react with the specific colored antibody conjugates and form a colored line at the test line region of the membrane. Absence of this colored line suggests a negative result. To serve as a procedural control, a colored line will always appear at the control line region if the test has been performed properly. III. Specimen Collection/Treatment A. Specimen: Acceptable: Urine and serum specimens Unacceptable: Specimens from other sources. B. Collection Container: Urine: Clean, dry collection container. A first morning specimen is preferred; however, urines collected any time of day may be used. Serum: Collect aseptically into a clean tube without anticoagulants. C. Specimen Storage: Urine and serum samples may be stored at 2-8 C up to 48 hours. For prolonged storage, specimens may be frozen and stored below -20 C. Frozen specimens should be thawed and mixed before testing. D. Handling Precautions: Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow the standard procedures for proper disposal of specimens.

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet IV. Reagents and Equipment A. Reagents and Materials Provided Test Devices Disposable specimen droppers Package insert B. Reagents and Materials not Provided Specimen collection container Timer C. Storage and Stability Store as packaged in the sealed pouch at 2-30 C. The test device is stable through the expiration date printed on the sealed pouch. The test device must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date. V. Quality Control Internal Procedural Controls Internal procedural controls are included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. A clear background is an internal negative background control. If the test is working properly, the background in the result area should be white to light pink and not interfere with the ability to read the test result. External Procedural Controls It is recommended that a positive hcg control and a negative hcg control be evaluated to verify proper test performance. Urine controls should be used when testing urine. It is recommended that federal, state, and local guidelines be followed. When correct control results are not obtained, do not report patient results. Services at 877-441-7440. Contact Technical VI. Precautions For professional in vitro diagnostic use only. Do not use after the expiration date. The test device should remain in the sealed pouch until use. All specimens should be considered potentially hazardous and handled in the same manner as an infectious agent. The test device should be discarded in a proper biohazard container after testing. The test device should not be reused. VII. Test Procedure Specimen Collection and Handling: To collect urine specimen: A urine specimen must be collected in a clean and dry container. A first morning urine specimen is preferred since it generally contains the highest concentration of hcg; however, urine specimens collected at any time of the day may be used. Urine specimens exhibiting visible precipitates should be centrifuged, filtered, or allowed to settle to obtain a clear specimen for testing. To collect serum specimen: Blood should be collected aseptically into a clean tube without anticoagulants. Separate the serum from blood as soon as possible to avoid hemolysis. Use clear non-hemolyzed specimens when possible.

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Urine and serum specimen may be stored at 2-8 C for up to 48 hours prior to testing. For prolonged storage, specimens may be frozen and stored below -20 C. Frozen specimens should be thawed and mixed before testing. Test Procedure: Allow the test device, urine or serum, and/or controls to equilibrate to room temperature (15-30 C) prior to testing. 1. Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible. 2. Place the test device on a clean and level surface. Hold the dropper vertically and transfer 3 full drops of urine or serum (approx. 100 µl) to the specimen well of the test device, and then start the timer. Avoid trapping air bubbles in the specimen well. 3. Wait for the red line(s) to appear. Read the result at 3-4 minutes when testing a urine specimen, and at 5-6 minutes when testing a serum specimen. Do not interpret the results after the appropriate read time. It is important that the background is clear before the result is read. VIII. Interpretation of Test Results POSITIVE:* Two distinct red lines appear. One line should be in the control region (C) and another line should be in the test region (T). NOTE: A sample hcg concentration below the cut-off level of this test might result in a weak line appearing in the test region (T) after an extended period of time. The intensity of the red color in the test line region (T) will vary depending on the concentration of hcg present in the specimen. However, neither the quantitative value nor the rate of increase in hcg can be determined by this qualitative test. NEGATIVE: One red line appears in the control region (C). No apparent red or pink line appears in the test region (T). INVALID: Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test device. If the problem persists, discontinue using the test kit immediately and call 1-877-441-7440, Option 2 for Technical Assistance. *NOTE: The intensity of the red color in the test line region (T) will vary depending on the concentration of hcg present in the specimen. However, neither the quantitative value nor the rate of increase in hcg can be determined by this qualitative test. IX. Limitations 1. Very dilute urine specimens, as indicated by a low specific gravity, may not contain representative levels of hcg. If pregnancy is still suspected, a first morning urine specimen should be collected 48 hours later and tested. 2. False negative results may occur when the levels of hcg are below the sensitivity level of the test. When pregnancy is still suspected, a first morning urine specimen should be collected 48 hours later and tested. 3. Very low levels of hcg (less than 50 miu/ml) are present in urine specimen shortly after implantation. However, because a significant number of first trimester pregnancies terminate for natural reasons, (5) a test result that is weakly positive should be confirmed by retesting with a first morning urine specimen collected 48 hours later. 4. This test reliably detects intact hcg up to 500,000 miu/ml. It does not reliably detect hcg degradation products, including free-beta hcg and beta core fragments. Quantitative assays used to detect hcg may detect hcg degradation products and therefore may disagree with the results of the rapid test.

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet 5. A number of conditions other than pregnancy, including trophoblastic disease and certain nontrophoblastic neoplasms including testicular tumors, prostate cancer, breast cancer, and lung cancer, cause elevated levels of hcg.(6-7) Therefore, the presence of hcg in urine specimen should not be used to diagnose pregnancy unless these conditions have been ruled out. 6. As with any assay employing mouse antibodies, the possibility exists for interference by human anti-mouse antibodies (HAMA) in the specimen. Specimens from patients who have received preparations for monoclonal antibodies for diagnosis or therapy may contain HAMA. Such specimens may cause false positive or false negative results. 7. This test provides a presumptive diagnosis for pregnancy. A confirmed pregnancy diagnosis should only be made by a physician after all clinical and laboratory findings have been evaluated. X. Expected Values Negative results are expected in healthy non-pregnant women and healthy men. Healthy pregnant women have hcg present in their urine and serum specimens. The amount of hcg will vary greatly with gestational age and between individuals. Sure-Vue Serum/Urine hcg-stat has a sensitivity of 10 miu/ml in serum and 20 miu/ml in urine and is capable of detecting pregnancy as early as 1 day after the first missed menses. XI. Performance Characteristics Accuracy A multi-center clinical evaluation was conducted comparing the results obtained using the Sure-Vue Serum/Urine hcg-stat to another commercially available urine membrane hcg test. The study included 100 specimen and both assays identified 50 negative and 50 positive results. The results demonstrated a 100% overall agreement (for an accuracy of >99%) of the Sure-Vue HCG Urine STAT when compared to the other Urine membrane hcg test. Sensitivity and Specificity The Sure-Vue Serum/Urine hcg-stat detects hcg at a concentration of 10 miu/ml or greater in serum and 20 miu/ml or greater in urine. The test has been standardized to the W.H.O. Third International Standard. The addition of LH (300 miu/ml), FSH (1,000 miu/ml), and TSH (1,000 μiu/ml) to negative (0 miu/ml hcg) and positive (10 miu/ml in serum and 20 miu/ml hcg in urine) specimens showed no cross-reactivity. Interfering Substances The following potentially interfering substances were added to hcg negative and positive specimens. Acetaminophen 20 Cocaine 10 Ibuprofen 20 Acetone 1,000 Codeine 10 Methadone 10 Acetylsalicylic Acid 20 Cholesterol 500 Methamphetamine 10 Acetoacetic Acid 2,000 Creatine 20 Methanol 10% Ampicillin 20 Dextramethorphan 20 Morphine 0.6 Ascorbic Acid 20 DMSO 5% Oxalic Acid 40 Atropine 20 EDTA 80 Phenothiazine 20 Albumin 2,000 Ephedrine 20 Phenylpropanolamine 20 β-hydroxybutyrate salt 2,000 Ethanol 1% Pregnanediol 2 Benzoylecgonine 10 Estriol 2 Salicylic Acid 20 Bilirubin 20 Estrone 3-Sulfate 10 Tetracycline 20 Brompheniramine 20 Gentisic Acid 20 Triglycerides 1,200 Caffeine 20 Glucose 2,000 Theophylline 20 Canabinol 10 Hemoglobin 1,000 Urea 2,000

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Clomiphene 100 Heroin 1 Uric acid 20 None of the substances at the concentration tested interfered in the assay. XII. References 1. Batzer FR. Hormonal evaluation of early pregnancy, Fertil. Steril. 1980; 34(1): 1-13 2. Catt KJ, ML Dufau, JL Vaitukaitis Appearance of hcg in pregnancy plasma following the initiation of implantation of the blastocyte, J. Clin. Endocrinol. Metab. 1975; 40(3): 537-540 3. Braunstein GD, J Rasor, H. Danzer, D Adler, ME Wade Serum human chorionic gonadotropin levels throughout normal pregnancy, Am. J. Obstet. Gynecol. 1976; 126(6): 678-681 4. Lenton EA, LM Neal, R Sulaiman Plasma concentration of human chorionic gonadotropin from the time of implantation until the second week of pregnancy, Fertil. Steril. 1982; 37(6): 773-778 5. Steier JA, P Bergsjo, OL Myking Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion and removed ectopic pregnancy, Obstet. Gynecol. 1984; 64(3): 391-394 6. Dawood MY, BB Saxena, R Landesman Human chorionic gonadotropin and its subunits in hydatidiform mole and choriocarcinoma, Obstet. Gynecol. 1977; 50(2): 172-181 7. Braunstein GD, JL Vaitukaitis, PP Carbone, GT Ross Ectopic production of human chorionic gonadotropin by neoplasms, Ann. Intern Med. 1973; 78(1): 39-45 8. Sure-Vue Serum/HCG Urine STAT Package Insert

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Sure-Vue is a registered trademark of Fisher Scientific Company, LLC. All rights reserved.

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Laboratory Name: Laboratory Address: Test Procedure Review Sheet Date of this packet: Supervisor Date Reviewed Supervisor Date Reviewed 7

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Sure-Vue Serum/Urine hcg-stat Validation Form Account Name: Address: Telephone: Sure-Vue Serum/Urine hcg-stat Lot #: Date: Supervisor Signature: Record the results from reference samples below. Record the Sample #, the Sure-Vue Serum/Urine hcg-stat results, Tester s Initials, and any comments. After the Sure-Vue Serum/Urine hcg-stat results have been recorded (positive or negative) then record the Expected Results (positive or negative). Sample # 1 Expected Results Sure-Vue Serum/Urine hcg- STAT Result Tester s Initials Comments 2 3 4 5 6 7 8 9 10 8

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet 9

Sure-Vue Serum/Urine hcg-stat CLSI + More Packet Sure-Vue Serum/Urine hcg-stat Validation Form Sample # 11 Expected Results Sure-Vue Serum/Urine hcg- STAT Result Tester s Initials Comments 12 13 14 15 16 17 18 19 20 Reviewed By: 10

Sure-Vue HCG Urine STAT CLSI + More Waived Packet Name of Facility: Use this coversheet with each new shipment. Sure-Vue Serum/Urine hcg-stat Quality Control Sure-Vue Serum/Urine hcg-stat Card Kit Lot# Expiration Date Date Received Received By Whom 1 st week open date Date Kit Positive Control Kit Negative Control Performer s Initials 2 nd week (if applicable) 3 rd week (if applicable) 4 th week (if applicable) 5 th week (if applicable) 6 th week (if applicable) Reviewed by: Date: CLSI-0004 Rev. 1 11

Sure-Vue HCG Urine STAT CLSI + More Waived Packet Lot Number Sure-Vue Serum/Urine hcg-stat Quality Control and Patient Record Exp. Date Alere recommends that external positive and negative controls be run for each new lot. Record the Date, Patient s Name, Patient Test Result, Internal Control Results and the performer s initials. Positive Internal Control = the red line appearing at the control line position; Negative Internal Control = background color should be clear within 10 minutes. Date Patient Name Patient ID Number Patient Results Internal Control Comments Tech + - Reviewed By: CLSI-0004 Rev. 1 Date: 12

Sure-Vue HCG Urine STAT CLSI + More Waived Packet Quality Assessment Review Form and Checklist These forms are used for periodical review of the patient testing process. These should be filed with the quality assessment records. Date/ Quality Assessment Activity Initials Patient Test Management: Evaluate criteria for specimen submission, handling, and rejection; test results requisitions and reporting, accuracy and reliability of reports. Comments Quality Control: Assess calibration and control data, reference range verification, errors in reporting results, corrective actions taken with appropriate documentation records. Proficiency Testing: Review the effectiveness of corrective actions taken for unsatisfactory performance or failures. Comparison of Test Results: Review at least semi-annually comparative results for multiple methods, instruments, or site correlations when more than one procedure exists. Relationship of Patient Test Information to Test Results: Evaluate patient test reports for accuracy of patient information, test results, and normal ranges. Identify and evaluate results inconsistent with Patient's age, sex, diagnosis, and other test parameters. Personnel: Evaluate the effectiveness of policies and procedures for assuring employees competence of testing and reporting test results. Communications: Evaluate documented problems and corrective actions that occur between the laboratory and the authorized individual who orders or receives the test result. Complaint Investigation: Evaluate documented complaints and corrective actions. Quality Assessment Reviews with Staff: Document discussion with Staff regarding identified problems and corrective actions during the QA review.

Sure-Vue HCG Urine STAT CLSI + More Waived Packet Corrective Action Form Problem/Error Corrective Action Laboratory Performer: Laboratory Director: Date: Date:

Sure-Vue HCG Urine STAT CLSI + More Waived Packet Tips for Successful PT Performance Strictly follow the PT provider s storage or handling requirement before testing PT specimens. o Analyze PT specimens within the time frame provided by the PT provider. o Contact the PT provider promptly when specimens are received damaged. You may be able to receive a replacement immediately. o Avoid clerical error when filling out PT answer sheets. Be sure to enter the correct result next to the correct analyte on the answer form. o Remember to identify the instrument or method you are using to perform your PT so you are graded among your peer group. o Make copies of all answer forms before submitting them to your PT provider.

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet Certification of Training This is to verify that personnel responsible for running the Sure-Vue Serum/Urine hcg-stat Test at have been thoroughly in-serviced on the test and the test procedure. This has included: Review of the package insert Demonstration of the product assay Successful performance of the Sure-Vue Serum/Urine hcg-stat Test and interpretation of results Names of the personnel who have been trained with the Sure-Vue Serum/Urine hcg-stat Test and are responsible for reporting patient results: PRINT NAME SIGNATURE DATE Signature of Medical Director(s) responsible for personnel and testing: Signature Signature Trainer Date Date Date

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet Equipment: Name of Facility: TEMPERATURE LOG To be recorded at the beginning of each workday. Temperature Range: Date C Initials Adjustments Date C Initials Adjustments

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet TEMPERATURE LOG Equipment: Name of Facility: To be recorded at the beginning of each workday. Temperature Range: Date C Initials Adjustments Date C Initials Adjustments

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet TEMPERATURE LOG Equipment: Lab Refrigerator Name of Facility: To be recorded at the beginning of each workday. Temperature Range: 2-8 C Date C Initials Adjustments Date C Initials Adjustments

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet Test Procedure Review Supervisor Date Reviewed Supervisor Date Reviewed

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet Sure-Vue Serum/Urine hcg-stat Competency Assessment We have provided you with a written quiz that can be administered to all testing personnel as part of their competency assessment. A Competency Assessment Checklist has been created that can be used to verify and document that all areas of competency for the Sure-Vue Serum/Urine hcg-stat have been evaluated. Sure-Vue Serum/Urine hcg-stat Quiz Answer Key 1. F The SureVue hcg Serum/Urine STAT kit may be stored at refrigerated or at room temperature (2-30 C). 2. F The SureVue hcg Serum/Urine STAT test cassettes should remain stored in the pouch until ready to test. 3. T The urine and serum specimens may be refrigerated up to 48 hours prior to testing. 4. F Three drops of the specimen should be added to the sample well using the kit pipette. 5. F The detection limit of the SureVue hcg Serum/Urine STAT kit is 10 miu/ml for serum and 20 miu/ml for urine. 6. T The SureVue hcg Serum/Urine STAT cassette should be at room temperature prior to testing. 7. F If the red control line fails to appear, the test is invalid. 8. T The SureVue hcg Serum/Urine STAT test may be read at 3 minutes for urine specimens and 5 minutes for serum specimens. 9. F The SureVue hcg Serum/Urine STAT test should not be read after 4 minutes for urine and 6 minutes for serum. 10. T If the red control line fails to appear, the test is invalid.

Sure-Vue Serum/Urine hcg-stat CLSI + More Waived Packet Testing Personnel Competency Assessment Test Method: Sure-Vue Serum/Urine hcg-stat Test Procedure Satisfactory Unsatisfactory Observation of Test Performance: Patient Preparation (if applicable) Specimen Handling/Processing Testing Recording/Reporting Results Assessment of Test Performance Using Known Samples Review of Records: Patient/Quality Control Log Sheet Records Proficiency Testing Records Assessment of Problem Solving Skills (Attach all supporting documents) Evaluator: Employee: Not Applicable Date: Comments/Corrective Actions

Sure-Vue Serum/hCG Urine STAT CLSI + More Waived Packet Sure-Vue Serum/Urine hcg-stat Quiz Name: Date: Circle T (True) or F (False) for each Question: 1. The Sure-Vue Serum/Urine hcg-stat cassette must be refrigerated at 2-8 C. 2. The Sure-Vue Serum/Urine hcg-stat test pouches may be opened 1 hour before the test is performed. 3. Urine and serum sample may be refrigerated up to 48 hours prior to testing. 4. Four drops of the specimen are added to the Sure-Vue Serum/Urine hcg-stat test. 5. The Sure-Vue Serum/Urine hcg-stat test detection limit is 20 miu/ml for both serum and urine specimens. 6. The Sure-Vue Serum/Urine hcg-stat test cassette should be at room temperature before performing a test. 7. A Sure-Vue Serum/Urine hcg-stat test cassette without a red line at the control region and a red line at the test region may be reported as positive. 8. The Sure-Vue Serum/Urine hcg-stat test may be read at 3 minutes for urine specimens and 5 minutes for serum specimens. 9. The Sure-Vue Serum/Urine hcg-stat test may be read at 20 minutes 10. If a red line is not visible at the control region, the Sure-Vue Serum/Urine hcg-stat test result is invalid. T T T T T T T T T T F F F F F F F F F F Page 1 of 6